Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells

References

• Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 34:43–50.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37:99–108.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Kulkarni GT. 2013. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm. 40:1–11.
   PubMed Web of Science ®Google Scholar
• Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. 2007. Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng. 13:589–599.
   PubMedGoogle Scholar
• Bhatia SR, Khattak SF, Roberts SC. 2005. Polyelectrolytes for cell encapsulation. Curr Opin Colloid Interface Sci. 10:45–51.
   Web of Science ®Google Scholar
• Calasan J, Al-Salami H, Mikov M. 2012. Bile acids and probiotics could help treating diabetes. FEBS J. 279:267–267.
   Web of Science ®Google Scholar
• Claiborn KC, Stoffers DA. 2008. Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. Mt Sinai J Med. 75:362–371.
   PubMedGoogle Scholar
• Codario R. 2011. Pathophysiology of Type-2 diabetes In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Totowa, NJ: Humana Press, pp. 1–14.
   Google Scholar
• de Vos P, de Haan BJ, Kamps JA, Faas MM, Kitano T. 2007. Zeta- potentials of alginate-PLL capsules: a predictive measure for biocompatibility?J Biomed Mater Res A. 80:813–819.
   PubMed Web of Science ®Google Scholar
• Dusseault J, Leblond FA, Robitaille R, Jourdan G, Tessier J, Ménard M, et al. 2005. Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers. Biomaterials. 26:1515–1522.
   PubMed Web of Science ®Google Scholar
• Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, et al. 1993. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig Dis Sci. 38:1291–1296.
   PubMed Web of Science ®Google Scholar
• Harlan DM, Rother KI, Robertson R. 2004. Islet transplantation as a treatment for diabetes. N Engl J Med. 350:2104.
   PubMed Web of Science ®Google Scholar
• Jiin WY. 2000. Development of new polycations for cell encapsulation with alginate. Mater Sci Eng. 1:59–63.
   Google Scholar
• Lalic-Popovic M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, Mikov M. 2013. Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. J Diabetes Res. 2013:598603.
   PubMed Web of Science ®Google Scholar
• Malisova L, Kováčová Z, Koc M, Kračmerová J, Stich V, Rossmeislová L. 2013. Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 8:e82086.
   PubMed Web of Science ®Google Scholar
• Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. 1998. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 31:111–118.
   PubMed Web of Science ®Google Scholar
• Martinez-Moya P, Romero-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, et al. 2013. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 15:372–380.
   PubMed Web of Science ®Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 33:137–142.
   PubMed Web of Science ®Google Scholar
• Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, Fawcett JP. 2006. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. FEBS J. 273:210–210.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014a. A complex microencapsulated system: a platform for optimised oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014b. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov9:150–157.
   PubMed Web of Science ®Google Scholar
• Nafea EH, Marson A, Poole-Warren LA, Martens PJ. 2011. Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels. J Control Release. 154:110–122.
   PubMed Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Al-Salami H. 2013. Potentials and limitations of bile acids in Type 2 diabetes mellitus: Applications of microencapsulation as a novel oral delivery system. J Endocrinol. Diabetes Mellitus. 1:49–59.
   Google Scholar
• Nolan CJ, Damm P, Prentki M. 2011. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 378:169–181.
   PubMed Web of Science ®Google Scholar
• Pal D, Nayak AK. 2011. Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules. AAPS PharmSciTech. 12:1431–1441.
   PubMed Web of Science ®Google Scholar
• Pal D, Nayak AK. 2012. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro-in vivo evaluation. Drug Deliv. 19:123–131.
   PubMed Web of Science ®Google Scholar
• Puri S, Hebrok M. 2012. Diabetic beta cells: to be or not to be?Cell. 150:1103–1104.
   PubMed Web of Science ®Google Scholar
• Rokstad AM, Lacík I, de Vos P, Strand BL. 2013. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 67–68:111–130.
   PubMed Web of Science ®Google Scholar
• Rokstad AM, Lacík I, de Vos P, Strand BL. 2014. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 67–68C: 111–130.
   Web of Science ®Google Scholar
• Rudi J, Schlenker T, Raedsch R, Waldherr R, Zorn M, Stremmel W. 1995. Effect of ursodeoxycholic acid on biochemical parameters, hepatocyte proliferation and liver histology in galactosamine hepatitis in the rat. Res Exp Med (Berl). 195:309–315.
   PubMedGoogle Scholar
• Schneider S, Feilen PJ, Slotty V, Kampfner D, Preuss S, Berger S, et al. 2001. Multilayer capsules: a promising microencapsulation system for transplantation of pancreatic islets. Biomaterials. 22:1961–1970.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 365:1333–1346.
   PubMed Web of Science ®Google Scholar
• Takka S, Cali AG. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23–29.
   PubMed Web of Science ®Google Scholar
• Taylor R. 2013. Type 2 diabetes: etiology and reversibility. Diabetes Care. 36:1047–1055.
   PubMed Web of Science ®Google Scholar
• Thanos CG, Bintz BE, Emerich DF. 2007a. Stability of alginate- polyornithine microcapsules is profoundly dependent on the site of transplantation. J Biomed Mater Res A. 81:1–11.
   PubMed Web of Science ®Google Scholar
• Thanos CG, Calafiore R, Basta G, Bintz BE, Bell WJ, Hudak J, et al. 2007b. Formulating the alginate-polyornithine biocapsule for prolonged stability: evaluation of composition and manufacturing technique. J Biomed Mater Res A. 83:216–224.
   PubMed Web of Science ®Google Scholar
• Uludag H, Sefton MV. 1990. Colorimetric assay for cellular activity in microcapsules. Biomaterials. 11:708–712.
   PubMed Web of Science ®Google Scholar
• Urbanska AM, Bhathena J, Prakash S. 2007. Live encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate-chitosan microcapsules. Can J Physiol Pharmacol. 85:884–893.
   PubMed Web of Science ®Google Scholar
• Weir GC. 2013. Islet encapsulation: advances and obstacles. Diabetologia. 56:1458–1461.
   PubMed Web of Science ®Google Scholar
• Wong H, Chang TM. 1991. The microencapsulation of cells within alginate poly-L-lysine microcapsules prepared with the standard single step drop technique: histologically identified membrane imperfections and the associated graft rejection. Biomater Artif Cells Immobilization Biotechnol. 19:675–686.
   PubMed Web of Science ®Google Scholar